Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
Yvette Fairfax, Shareholder of KOELIS, shared a post on LinkedIn:
“The approval of the first gene therapy for Wiskott-Aldrich syndrome is a profound milestone for families facing a disorder linked to immune dysfunction, bleeding risk, and repeated infections.
For affected children, this kind of therapy is not just an incremental medical improvement. It has the potential to reduce hospital crises, improve stability, and reshape daily life in a much more fundamental way.But the controversy begins right after celebration.
Gene therapies often represent the best of science and the hardest realities of healthcare economics at the same time. A breakthrough can be medically transformative and still remain financially out of reach for families trapped in slow reimbursement systems or unequal access pathways.
In the U.S., UK, and Canada, rare-disease medicine keeps exposing the same structural tension: scientific innovation moves faster than fair access. If a one-time treatment can prevent years of suffering, complications, and repeated medical costs, waiting too long to fund it may be both unjust and inefficient.
Should public systems approve payment earlier for these therapies instead of forcing families through exhausting access battles first?”
Stay updated with Hemostasis Today.
-
Oct 22, 2026, 14:26Khaled Musallam: Longevity and Healthy Aging in Thalassemia
-
Oct 22, 2026, 14:26Deise Catamo Vaz: Two Years of Growth and a New Way of Seeing the World of Stroke
-
Oct 22, 2026, 14:24Yara Mohamed: A Silent Killer Plots his Victim’s Death Over Years
-
Oct 22, 2026, 14:19Shailendra Singh: Two Different Pulmonary Embolism Cases, One Critically Important Lesson
-
Oct 22, 2026, 14:14Caitlin Raymond: Estimating Infection Rates After Therapeutic Plasma Exchange in a Large Real-World Population
-
Oct 22, 2026, 14:11Lesley Van Wyk: The Bombay Blood Group Explained
-
Oct 22, 2026, 14:10Mandy Moore’s Pregnancy Journey With Immune Thrombocytopenia
-
Oct 22, 2026, 14:07Xavier Griffin: Celebrating NIHR-Funded Trials and Exploring How to Do Research Better
-
Oct 22, 2026, 13:46Claire van Teunenbroek: Recruiting and Retaining Young Blood Donors Through Better Coordination